Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

[This corrects the article DOI: 10.3389/fpsyt.2024.

Corrigendum: Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression.

[This corrects the article DOI: 10.3389/fnins.2023.

Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression.

Drug-resistant mental disorders, particularly treatment-resistant depression, pose a significant medical and social problem. To address this challenge, modern psychiatry is constantly exploring the use of novel treatment methods, including biological treatments, such as transcranial magnetic stimulation (TMS), and novel rapid-acting antidepressants, such as ketamine. While both TMS and ketamine demonstrate high effectiveness in reducing the severity of depressive symptoms, some patients still do not achieve the desired improvement.

Oxidative Stress Biomarkers among Schizophrenia Inpatients.

Background: Finding the associations between schizophrenia symptoms and the biomarkers of inflammation, oxidative stress and the kynurenine pathway may lead to the individualization of treatment and increase its effectiveness.

Methods: The study group included 82 schizophrenia inpatients. The Positive and Negative Symptoms Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS) and the Calgary Depression in Schizophrenia Scale were used for symptom evaluation.